Could a higher dose of rifampicin cut TB treatment time for kids?

NCT ID NCT07656012

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a higher dose of the drug rifampicin can safely shorten tuberculosis treatment for children aged 3 months to 10 years. About 230 children with drug-susceptible TB will receive either the standard or a higher rifampicin dose, with treatment duration adjusted. The goal is to find a shorter regimen that works as well as the current standard, potentially improving outcomes for children worldwide.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rifampicin (higher dose) combined with isoniazid, pyrazinamide, and ethambutol
What this could lead to: If successful, this could lead to a shorter, more convenient treatment for children with tuberculosis, reducing the burden on families and healthcare systems.
What could go wrong: This is a Phase 2 trial with only 230 children, so results are preliminary. Higher doses may cause more side effects, and shorter treatment might not cure everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Socios en Salud Sucursal Peru

Lima, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.